É. Alamartine

Excessive body weight as a new independent risk factor for clinical and pathological progression in primary IgA nephritis

Fabrice Bonnet, Carole Deprele, Agnès Sassolas et al. · American Journal of Kidney Diseases · 2001 · 311 citations

Medicine, Nephrology, Pathology +10

Prognostic Factors in Mesangial IgA Glomerulonephritis: An Extensive Study With Univariate and Multivariate Analyses

É. Alamartine, Jean-Charles Sabatier, Claude Guérin et al. · American Journal of Kidney Diseases · 1991 · 281 citations

Medicine, Immunology, Nephrology +12

Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy

Jonathan Barratt, Richard Lafayette, Jens Kristensen et al. · Kidney International · 2022 · 215 citations · Full text

Pharmacy, Nephrology, Pharmacotherapy +13

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Hiddo J.L. Heerspink, Jai Radhakrishnan, Charles E. Alpers et al. · The Lancet · 2023 · 215 citations · Full text

Medicine, Internal Medicine, Nephrology +12

INDUCTION VERSUS NONINDUCTION IN RENAL TRANSPLANT RECIPIENTS WITH TACROLIMUS-BASED IMMUNOSUPPRESSION1

Georges Mourad, Val rie Garrigue, Jean‐Paul Squifflet et al. · Transplantation · 2001 · 190 citations

Medicine, Immunology, Nephrology +16